Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib

Peter Pyrko, Adel Kardosh, Yen Ting Liu, Nathaniel Soriano, Wenyong Xiong, Robert H. Chow, Jasim Uddin, Nicos A. Petasis, Austin K. Mircheff, Robert A. Farley, Stan G. Louie, Thomas C. Chen, Axel H. Schönthal

Research output: Contribution to journalArticle

96 Citations (Scopus)

Abstract

A drawback of extensive coxib use for antitumor purposes is the risk of life-threatening side effects that are thought to be a class effect and probably due to the resulting mbalance of eicosanoid levels. 2,5-Dimethyl-celecoxib (DMC) is a close structural analogue of the selective cyclooxygenase-2 inhibitor celecoxib that lacks cyclooxygenase-2-inhibitory function but that nonetheless is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. To further establish the potential usefulness of DMC as an anticancer agent, we compared DMC and various coxibs and nonsteroidal anti-inflammatory drugs with regard to their ability to stimulate the endoplasmic reticulum (ER) stress response (ESR) and subsequent apoptotic cell death. We show that DMC increases intracellular free calcium levels and potently triggers the ESR in various tumor cell lines, as indicated by transient inhibition of protein synthesis, activation of ER stress-associated proteins GRP78/BiP, CHOP/GADD153, and caspase-4, and subsequent tumor cell death. Small interfering RNA-mediated knockdown of the protective chaperone GRP78 further sensitizes tumor cells to killing by DMC, whereas inhibition of caspase-4 prevents drug-induced apoptosis. In comparison, celecoxib less potently replicates these effects of DMC, whereas none of the other tested coxibs (rofecoxib and valdecoxib) or traditional nonsteroidal anti-inflammatory drugs (flurbiprofen, indomethacin, and sulindac) trigger the ESR or cause apoptosis at comparable concentrations. The effects of DMC are not restricted to in vitro conditions, as this drug also generates ER stress in xenografted tumor cells in vivo, concomitant with increased apoptosis and reduced tumor growth. We propose that it might be worthwhile to further evaluate the potential of DMC as a non-coxib alternative to celecoxib for anticancer purposes.

Original languageEnglish (US)
Pages (from-to)1262-1275
Number of pages14
JournalMolecular cancer therapeutics
Volume6
Issue number4
DOIs
StatePublished - Apr 1 2007
Externally publishedYes

Fingerprint

Celecoxib
Endoplasmic Reticulum Stress
Cell Death
Calcium
Neoplasms
Cyclooxygenase 2 Inhibitors
Apoptosis
Caspases
Pharmaceutical Preparations
2,5-dimethylcelecoxib
Anti-Inflammatory Agents
Sulindac
Flurbiprofen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. / Pyrko, Peter; Kardosh, Adel; Liu, Yen Ting; Soriano, Nathaniel; Xiong, Wenyong; Chow, Robert H.; Uddin, Jasim; Petasis, Nicos A.; Mircheff, Austin K.; Farley, Robert A.; Louie, Stan G.; Chen, Thomas C.; Schönthal, Axel H.

In: Molecular cancer therapeutics, Vol. 6, No. 4, 01.04.2007, p. 1262-1275.

Research output: Contribution to journalArticle

Pyrko, P, Kardosh, A, Liu, YT, Soriano, N, Xiong, W, Chow, RH, Uddin, J, Petasis, NA, Mircheff, AK, Farley, RA, Louie, SG, Chen, TC & Schönthal, AH 2007, 'Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib', Molecular cancer therapeutics, vol. 6, no. 4, pp. 1262-1275. https://doi.org/10.1158/1535-7163.MCT-06-0629
Pyrko, Peter ; Kardosh, Adel ; Liu, Yen Ting ; Soriano, Nathaniel ; Xiong, Wenyong ; Chow, Robert H. ; Uddin, Jasim ; Petasis, Nicos A. ; Mircheff, Austin K. ; Farley, Robert A. ; Louie, Stan G. ; Chen, Thomas C. ; Schönthal, Axel H. / Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. In: Molecular cancer therapeutics. 2007 ; Vol. 6, No. 4. pp. 1262-1275.
@article{f0673d4646344fe6b2772b677630ea53,
title = "Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib",
abstract = "A drawback of extensive coxib use for antitumor purposes is the risk of life-threatening side effects that are thought to be a class effect and probably due to the resulting mbalance of eicosanoid levels. 2,5-Dimethyl-celecoxib (DMC) is a close structural analogue of the selective cyclooxygenase-2 inhibitor celecoxib that lacks cyclooxygenase-2-inhibitory function but that nonetheless is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. To further establish the potential usefulness of DMC as an anticancer agent, we compared DMC and various coxibs and nonsteroidal anti-inflammatory drugs with regard to their ability to stimulate the endoplasmic reticulum (ER) stress response (ESR) and subsequent apoptotic cell death. We show that DMC increases intracellular free calcium levels and potently triggers the ESR in various tumor cell lines, as indicated by transient inhibition of protein synthesis, activation of ER stress-associated proteins GRP78/BiP, CHOP/GADD153, and caspase-4, and subsequent tumor cell death. Small interfering RNA-mediated knockdown of the protective chaperone GRP78 further sensitizes tumor cells to killing by DMC, whereas inhibition of caspase-4 prevents drug-induced apoptosis. In comparison, celecoxib less potently replicates these effects of DMC, whereas none of the other tested coxibs (rofecoxib and valdecoxib) or traditional nonsteroidal anti-inflammatory drugs (flurbiprofen, indomethacin, and sulindac) trigger the ESR or cause apoptosis at comparable concentrations. The effects of DMC are not restricted to in vitro conditions, as this drug also generates ER stress in xenografted tumor cells in vivo, concomitant with increased apoptosis and reduced tumor growth. We propose that it might be worthwhile to further evaluate the potential of DMC as a non-coxib alternative to celecoxib for anticancer purposes.",
author = "Peter Pyrko and Adel Kardosh and Liu, {Yen Ting} and Nathaniel Soriano and Wenyong Xiong and Chow, {Robert H.} and Jasim Uddin and Petasis, {Nicos A.} and Mircheff, {Austin K.} and Farley, {Robert A.} and Louie, {Stan G.} and Chen, {Thomas C.} and Sch{\"o}nthal, {Axel H.}",
year = "2007",
month = "4",
day = "1",
doi = "10.1158/1535-7163.MCT-06-0629",
language = "English (US)",
volume = "6",
pages = "1262--1275",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2,5-dimethyl-celecoxib, a non-coxib analogue of celecoxib

AU - Pyrko, Peter

AU - Kardosh, Adel

AU - Liu, Yen Ting

AU - Soriano, Nathaniel

AU - Xiong, Wenyong

AU - Chow, Robert H.

AU - Uddin, Jasim

AU - Petasis, Nicos A.

AU - Mircheff, Austin K.

AU - Farley, Robert A.

AU - Louie, Stan G.

AU - Chen, Thomas C.

AU - Schönthal, Axel H.

PY - 2007/4/1

Y1 - 2007/4/1

N2 - A drawback of extensive coxib use for antitumor purposes is the risk of life-threatening side effects that are thought to be a class effect and probably due to the resulting mbalance of eicosanoid levels. 2,5-Dimethyl-celecoxib (DMC) is a close structural analogue of the selective cyclooxygenase-2 inhibitor celecoxib that lacks cyclooxygenase-2-inhibitory function but that nonetheless is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. To further establish the potential usefulness of DMC as an anticancer agent, we compared DMC and various coxibs and nonsteroidal anti-inflammatory drugs with regard to their ability to stimulate the endoplasmic reticulum (ER) stress response (ESR) and subsequent apoptotic cell death. We show that DMC increases intracellular free calcium levels and potently triggers the ESR in various tumor cell lines, as indicated by transient inhibition of protein synthesis, activation of ER stress-associated proteins GRP78/BiP, CHOP/GADD153, and caspase-4, and subsequent tumor cell death. Small interfering RNA-mediated knockdown of the protective chaperone GRP78 further sensitizes tumor cells to killing by DMC, whereas inhibition of caspase-4 prevents drug-induced apoptosis. In comparison, celecoxib less potently replicates these effects of DMC, whereas none of the other tested coxibs (rofecoxib and valdecoxib) or traditional nonsteroidal anti-inflammatory drugs (flurbiprofen, indomethacin, and sulindac) trigger the ESR or cause apoptosis at comparable concentrations. The effects of DMC are not restricted to in vitro conditions, as this drug also generates ER stress in xenografted tumor cells in vivo, concomitant with increased apoptosis and reduced tumor growth. We propose that it might be worthwhile to further evaluate the potential of DMC as a non-coxib alternative to celecoxib for anticancer purposes.

AB - A drawback of extensive coxib use for antitumor purposes is the risk of life-threatening side effects that are thought to be a class effect and probably due to the resulting mbalance of eicosanoid levels. 2,5-Dimethyl-celecoxib (DMC) is a close structural analogue of the selective cyclooxygenase-2 inhibitor celecoxib that lacks cyclooxygenase-2-inhibitory function but that nonetheless is able to potently mimic the antitumor effects of celecoxib in vitro and in vivo. To further establish the potential usefulness of DMC as an anticancer agent, we compared DMC and various coxibs and nonsteroidal anti-inflammatory drugs with regard to their ability to stimulate the endoplasmic reticulum (ER) stress response (ESR) and subsequent apoptotic cell death. We show that DMC increases intracellular free calcium levels and potently triggers the ESR in various tumor cell lines, as indicated by transient inhibition of protein synthesis, activation of ER stress-associated proteins GRP78/BiP, CHOP/GADD153, and caspase-4, and subsequent tumor cell death. Small interfering RNA-mediated knockdown of the protective chaperone GRP78 further sensitizes tumor cells to killing by DMC, whereas inhibition of caspase-4 prevents drug-induced apoptosis. In comparison, celecoxib less potently replicates these effects of DMC, whereas none of the other tested coxibs (rofecoxib and valdecoxib) or traditional nonsteroidal anti-inflammatory drugs (flurbiprofen, indomethacin, and sulindac) trigger the ESR or cause apoptosis at comparable concentrations. The effects of DMC are not restricted to in vitro conditions, as this drug also generates ER stress in xenografted tumor cells in vivo, concomitant with increased apoptosis and reduced tumor growth. We propose that it might be worthwhile to further evaluate the potential of DMC as a non-coxib alternative to celecoxib for anticancer purposes.

UR - http://www.scopus.com/inward/record.url?scp=34248174933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248174933&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-06-0629

DO - 10.1158/1535-7163.MCT-06-0629

M3 - Article

C2 - 17431104

AN - SCOPUS:34248174933

VL - 6

SP - 1262

EP - 1275

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 4

ER -